CTOs on the Move

BioVectra

www.biovectra.com

 
BioVectra Inc. is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.biovectra.com
  • 11 Aviation Ave
    Charlottetown, PE CAN C1E 0A1
  • Phone: 866.883.2872

Executives

Name Title Contact Details

Funding

BioVectra raised $37M on 03/05/2019

Similar Companies

Cornerstone Pharmacy Services

Cornerstone Pharmacy Services LLC is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.

Pharmaprint Inc

Pharmaprint Inc is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Euro Pharma

Euro Pharma is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.